Man Group’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-749,342
| Closed | -$38.7M | – | 2348 |
|
|
2022
Q3 | $38.7M | Buy |
+749,342
| New | +$31M | 0.18% | 138 |
|
|
2022
Q2 | – | Sell |
-28,356
| Closed | -$711K | – | 2519 |
|
|
2022
Q1 | $711K | Buy |
+28,356
| New | +$797K | ﹤0.01% | 1479 |
|
|
2021
Q2 | – | Sell |
-75,677
| Closed | -$3.88M | – | 2147 |
|
|
2021
Q1 | $3.88M | Sell |
75,677
-32,490
| -30% | -$1.95M | 0.02% | 815 |
|
|
2020
Q4 | $6.7M | Buy |
108,167
+10,036
| +10% | +$575K | 0.03% | 634 |
|
|
2020
Q3 | $5.38M | Buy |
98,131
+8,020
| +9% | +$432K | 0.02% | 773 |
|
|
2020
Q2 | $5.18M | Buy |
90,111
+58,224
| +183% | +$3.17M | 0.03% | 644 |
|
|
2020
Q1 | $1.28M | Buy |
+31,887
| New | +$1.35M | 0.01% | 1047 |
|
|
2019
Q4 | – | Sell |
-72,465
| Closed | -$491K | – | 1948 |
|
|
2019
Q3 | $491K | Sell |
72,465
-49,295
| -40% | -$370K | ﹤0.01% | 1580 |
|
|
2019
Q2 | $1.13M | Buy |
121,760
+46,799
| +62% | +$542K | ﹤0.01% | 1487 |
|
|
2019
Q1 | $1.04M | Buy |
+74,961
| New | +$857K | ﹤0.01% | 1570 |
|
|
2018
Q4 | – | Sell |
-20,239
| Closed | -$255K | – | 2179 |
|
|
2018
Q3 | $255K | Buy |
+20,239
| New | +$244K | ﹤0.01% | 1983 |
|
Other funds holding CCXI
Man Group's CCXI Position: Q4 2022 in Review
Man Group sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 749,342 shares — an estimated $38.7M sold.
Man Group first reported a position in CCXI in Q3 2018 and held it in 11 quarters. The position peaked at $38.7M in Q3 2022. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- Man Group reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- Man Group sold 749,342 ChemoCentryx, Inc. shares in Q4 2022, an estimated $38.7M.
- Man Group first reported a position in ChemoCentryx, Inc. in Q3 2018 and held it in 11 quarters.
- Man Group's ChemoCentryx, Inc. position peaked at $38.7M in Q3 2022.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on Man Group's 13F filing for Q4 2022, filed 14 Feb 2023.